Obada Ababneh
@ObadaEAbabneh
Followers
492
Following
868
Media
47
Statuses
264
Postdoctoral fellow @MDAndersonNews Skoulidis lab. @JUSTEDUJO MD graduate. Aspiring physician-scientist in oncology.
Houston, TX
Joined August 2015
I am excited to announce that I will be joining Dr. @FSkoulidis's lab at @MDAndersonNews as a postdoctoral fellow. This marks a new chapter of my career after graduating from medical school. Couldn't be more excited for the upcoming adventure with the goal of #makecancerhistory
34
3
137
Honored to receive the International Early Career Investigator Award @AASLDtweets. Grateful for the mentors and collaborators who made this possible. @Wafa_Asha, always showing up with guidance and support. @ObadaEAbabneh, what you taught me still shapes how I work. #TLM2025
3
2
34
BREAKING NEWS The 2025 #NobelPrize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi “for their discoveries concerning peripheral immune tolerance.”
468
12K
29K
Approximately one-third of patients treated on TT 2 protocol and half of those treated on TT 3A protocol were alive at 15 to 20 years post-diagnosis. https://t.co/arHkrxLklO
@HadidiSamer @ObadaEAbabneh
0
3
13
Thrilled to share this exciting study @NatureMedicine. Largest integrative analysis of #sotorasib efficacy biomarkers to date. Grateful to all co- investigators and the Amgen team for their hard work and most of all to our patients. @MDAndersonNews #KRAS #NSCLC
7
60
202
We report @UAMSMyeloma the longest follow up of any myeloma phase III clinical trial @BloodAdvances @ASH_hematology #mmsm Long Term Follow up of Total Therapy IV: A Phase III Clinical Trial for Standard Risk Multiple Myeloma ➡️ https://t.co/14jmt9SjjR Median OS: 13.3 yrs 🧵
4
24
88
2023 was special year for me achieving many items on my bucket list; from graduating medical school @JUSTEDUJO, winning @AACR #GSITA and joining Dr. @FSkoulidis lab @MDAndersonNews. Happy new year for everyone. Hope 2025 will be blessed and successful year for everyone.
1
0
20
My first @sitcancer annual meeting! Excited to learn more about what's knew in immuno-oncology #SITC24
1
0
35
Welcome to Houston!!! A lot of talk about science but still we shifted somehow to talk about Irbid
Touchdown in Houston for #SITC24 But first things first, linking up with the homeboy @ObadaEAbabneh and lots of catching up to do 🫡
1
0
27
Thank you Allah for every blessing. I also couldn't achieve that without the continuous support of my family, mentors, and friends.
0
0
7
Thankful for the opportunity to work with Dr. @Dr_R_Kurzrock, Dr. Kato and Dr. @zacksurg. https://t.co/Vp68jVtksK
link.springer.com
Cancer and Metastasis Reviews - Immune checkpoint inhibitors have shaped the landscape of cancer treatment. However, many patients either do not respond or suffer from later progression. Numerous...
0
0
1
In this review, we comprehensively summarized TNFSF/TNRSF biological actions, their roles in cancer and IO adverse events, clinical trials results, discussed potential new ways to target these proteins and importantly their potential role as biomarkers.
1
0
1
Check out our new review! TNF and its cousins, the TNF superfamily, and their receptors are critical for immune functions and apoptosis. They play many roles, some are paradoxical! Most trials targeting TNFSF/TNFRSF members failed due to poor anti-tumor activity and/or toxicity.
2
0
20
Still, the rates are high compared to the general population and screening for these patients is important (see tables S6 and S7 for more details about cancer type). Thankful to Dr. @HadidiSamer and the team for giving me the opportunity to participate in this work.
0
0
4
Check out our newest paper. Our work represents, possibly, the longest follow-up study investigating second primary malignancies after tandem vs. single ASCT transplant across four trials in #mmsm. When adjusting for follow-up and death, Tandem did not increase the risk of SPMs.
Check our recent paper @UAMSMyeloma @AjHematology #mmsm : Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma ➡️ https://t.co/MhngkwZag3 ✅n=1379 ✅Median FU:16.6 yrs ✅SHM:5.6% (1 vs 2 transplants=no difference)
1
0
10
Alhamdulillah, I've graduated as an MD from @JUSTEDUJO, ranking among the top ten. Grateful to my family, esp. my mom, for unwavering support from day 1. Huge thanks to my mentors at JUST and abroad, and my friends who inspire me daily. Excited for the next chapter of my journey!
11
0
52
Check out our article about Postoperative Seizures in Meningioma Patients https://t.co/MQTh1qcwWD
4
4
22